Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukemia .- Jazz Pharmaceuticals
The approval of Vyxeos is based on results from a Phase III study of 309 adult patients, aged 60-75, with newly diagnosed t-AML or AML-MRC. The study met its primary endpoint as Vyxeos demonstrated a superior improvement in overall survival compared to the current conventional treatment group. The median overall survival for the Vyxeos treatment group was 9.6 months compared with 6.0 months for the current conventional treatment group.
Considered a rare disease, AML affects approximately 1,100 men and women in Canada annually. Though the number of AML cases has continued to rise, the current treatment regimen for patients with high-risk AML has remained the same for decades until now.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins